Dec. 12, 2019: A lot of catchup to do before “Ending the HIV Epidemic”; the value of online HIV self-test distribution; viral suppression is about more than basic HIV treatment services; effect of hormone therapy on PrEP levels.
Dec. 5, 2019: The value of pre-treatment drug resistance testing; resistance rates among viremic Americans; persistent pneumonia incidence among people with HIV; mixed HIV prevention results for the U.S. National HIV Strategy.
Timothy Ray Brown, known as "the Berlin patient," has begun taking PrEP to make sure he doesn't have to deal with an HIV diagnosis -- again.
Aug. 15, 2019: PCP continuity, ID specialization, and adherence; rules of HIV patient engagement; long-term benefits of financial incentives on adherence; headaches and TDF/FTC.
But given cost concerns, advocates question whether the benefits are enough to warrant dumping F/TDF as the go-to PrEP option.
A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.
The European Medicines Agenecy has noted a positive summary of opinion for the first generic combination of tenofovir/emtricitabine (Truvada).
Pharmacokinetic analysis informs estimates of how long it takes for PrEP to reach protective levels, and how long individuals would remain protected if they stop PrEP.
Pre-exposure prophylaxis, or PrEP, is an exciting new HIV prevention strategy that involves the ongoing use of anti-HIV drugs by an HIV-negative person in order to reduce their risk of becoming infected with HIV. Many types of PrEP are currently bein...
This article was reported by The Washington Post.
The Washington Post reported that US health officials recently advised healthy individuals at risk of HIV to take a daily dose of the drug Truvada, which cuts the risk of infection by more than 90 pe...